SynDevRx, Inc.   Report issue

For profit Phase 2
Founded: Cambridge MA United States (2007)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2016
NCT02743637
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

SynDevRx, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

eribulin (halaven) (1 trial)

sdx-7320 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2